752234-60-9Relevant academic research and scientific papers
Effect of cathepsin K inhibitors on bone resorption
Teno, Naoki,Masuya, Keiichi,Ehara, Takeru,Kosaka, Takatoshi,Miyake, Takahiro,Irie, Osamu,Hitomi, Yuko,Matsuura, Naoko,Umemura, Ichiro,Iwasaki, Genji,Fukaya, Hiroaki,Toriyama, Kazuhiro,Uchiyama, Noriko,Nonomura, Kazuhiko,Sugiyama, Ikuo,Kometani, Motohiko
experimental part, p. 5459 - 5462 (2009/07/09)
On the basis of the pyrrolopyrimidine core structure that was previously discovered, cathepsin K inhibitors having a spiro amine at the P3 have been explored to enhance the target, bone marrow, tissue distribution. Several spiro structures were identified with improved distribution toward bone marrow. The representative inhibitor 7 of this series revealed in vivo reduction in C-terminal telopeptide of type I collagen in rats and monkeys.
SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES
-
Page 19; 34-35, (2008/06/13)
The invention provides compounds of formula (I) or a pharmaceutically acceptable salt or ester thereof formula (I) wherein the symbols have the meaning as defined in the description. Said compounds are inhibitors of cathepsin K and/or cathepsin S and are useful for the treatment of diseases and medical conditions in which cathepsin K and/or cathepsin S is implicated, e.g. various disorders including neuropathic pain, inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis and tumours.
